Delayed gastric emptying and gastrointestinal motility effects — indication assessment
Slowed gastric transit, considered here both as a pharmacodynamic mechanism and as an adverse-effect surface relevant to procedural and anaesthetic risk.
§1Assessment
§1.1Definition
Slowed gastric transit, considered here both as a pharmacodynamic mechanism and as an adverse-effect surface relevant to procedural and anaesthetic risk.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Gastric emptying half-time by scintigraphy or breath test
- Residual gastric content at endoscopy or anaesthesia
- Gastrointestinal adverse-event incidence
§1.3State of the evidence
The Institute assesses 2 compounds in this indication, drawing on 6 trial records and 1 evidence synthesis. [1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917 · PMID 28910237
- Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009;374(9683):39–47. doi:10.1016/S0140-6736(09)60659-0 · PMID 19515413
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.